Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

Name: Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Author: Munster, Pamela

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. — المؤلف: Munster, Pamela — British journal of cancer 20190823

المؤلف: Munster, Pamela
النشر: British journal of cancer 20190823
الوصف: 1086-1093 p.
الموضوعات: Adult؛ Aged؛ Antineoplastic Combined Chemotherapy Protocols؛ Brain؛ Breast Neoplasms؛ Cyclophosphamide؛ Dose-Response Relationship, Drug؛ Doxorubicin